Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Seminars in Neurology|May 28, 2013
Natalizumab therapy for multiple sclerosisTobias Derfuss, Jens Kuhle, Raija Lindberg, et al.Journal of Neuroimmunology|December 29, 2005
CD24 and myosin light polypeptide 2 are involved in prevention of experimental autoimmune encephalomyelitis by myelin basic protein-pulsed dendritic cellsXuan Liu, Raija Lindberg, Bao-Guo Xiao, et al.Clinical Chemistry and Laboratory Medicine|April 13, 2016
Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and SimoaJens Kuhle, Christian Barro, Ulf Andreasson, et al.Therapeutic Advances in Neurological Disorders|February 6, 2023
Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosisIlaria Callegari, Mika Schneider, Vera Aebischer, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|January 17, 2018
Prediction of natalizumab anti-drug antibodies persistencyFlorian Deisenhammer, Marlies Jank, Anna Lauren, et al.The New England Journal of Medicine|January 26, 2007
Lack of association between antimyelin antibodies and progression to multiple sclerosisJens Kuhle, Christoph Pohl, Matthias Mehling, et al.Human Molecular Genetics|March 17, 2009
Pathway and network-based analysis of genome-wide association studies in multiple sclerosisSergio E Baranzini, Nicholas W Galwey, Joanne Wang, et al.Plos One|February 8, 2017
Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test resultsJenny Link, Ryan Ramanujam, Michael Auer, et al.Plos Medicine|October 30, 2020
Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortiumSigne Hässler, Delphine Bachelet, Julianne Duhaze, et al.Pageof 1